和黄医药(00013)举办最新研发进展投资者会议分享产品管线及业务进展

智通财经
Nov 03, 2025

智通财经APP讯,和黄医药(00013)发布公告,于2025年10月31日举行的投资者会议中分享最新关键研发和业务进展。此次活动重点展示了和黄医药在推进创新癌症和免疫疾病治疗方面的最新进展,包括介绍其新一代抗体靶向偶联药物(ATTC)平台,以及后期管线候选药物的最新进展。

和黄医药研发负责人兼首席医学官石明博士表示:“满足癌症和免疫疾病领域关键未被满足的医学需求是和黄医药的使命所在,驱动着我们持续致力推进创新疗法。ATTC平台有望重新定义癌症精准治疗,依托我们坚实的产品管线和合作策略,我们有信心能够为全球患者提供具有潜在变革性的癌症和免疫疾病治疗方案。”

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10